We examined clinical, morphologic, and cytogenetic features and ALL-1 (MLL, Html, H M I gene rearrangements in 17 cases of secondary leukemia that occurred 11 months to 9 years from diagnoses of primary cancers in children who received topoisomerase II inhibitors or developed secondary leukemias typical of those associated with this therapy. Primary diagnoses included nine solid tumors and eight leukemias. Ten secondary leukemias were acute myeloid leukemia (AML), one was of mixed lineage, two were acute lymphoblastic leukemia (ALL), and four presented as myelo- However, in one case of W a t r i c etoposiderelated AML with a t( 1 l ; 19)(q23;p13), we reported an 1 lq23 translocation breakpoint outside the ALL-I genomic breakpoint cluster.I8 Although a limited number of children have been examined, most molecular analyses of 1 1 q23 chromosomal breakpoints in secondary AML have involved ad~lts.'*.'~**~ The present study explores the molecular diversity and provides further clinical definition to DNA topoisomerase 11 inhibitor-related leukemia in a pediatric population.
breakpoint cluster region within the ALL1 (MLL, Htrxl, HRX) oncogene at band 1 lq23 for sporadic cases is disrupted in most reported cases of epipodophyllotoxin-related llq23
However, in one case of W a t r i c etoposiderelated AML with a t( 1 l ; 19)(q23;p13), we reported an 1 lq23 translocation breakpoint outside the ALL-I genomic breakpoint cluster.I8 Although a limited number of children have been examined, most molecular analyses of 1 1 q23 chromosomal breakpoints in secondary AML have involved ad~lts.'*.'~**~ The present study explores the molecular diversity and provides further clinical definition to DNA topoisomerase 11 inhibitor-related leukemia in a pediatric population.
MATERIALS AND METHODS

leukemia. 12.18-26
Leukemic specimens from children previously treated for a primary cancer and diagnosed with secondary leukemia were obtained from the Children's Hospital of Philadelphia (Philadelphia, PA), Dallas (Dallas, TX) and Cook-Fort Worth (Forth Worth, TX) Children's Hospitals, Children's Hospital of Cincinnati (Cincinnati, OH), Memorial Sloan Kettering Cancer Center (New York, NY), University of Connecticut Health Center (Farmington), Kaiser Permanente (Los Angeles, CA), and Indiana Oncology-Hematology Consultants (Indianapolis). Molecular studies were approved by the Institutional Review Board at the Children's Hospital of Philadelphia, and individual institutions had provisions either through consent for reference laboratory specimens or for the use of extra diagnostic materials for research. The diagnoses of secondary leukemia were made by morphologic and immunohistochemical examination of the marrow and by fluorescence-activated cell sorter analysis with standard monoclonal antibodies." Cytogenetic analyses were performed by individual Childrens Cancer Group-or Pediatric Oncology Groupapproved laboratories. Molecular analyses also were performed on the cell line B1, which was derived from t(4; 1 l)(q21;q23) secondary ALL cells.'' Leukemic marrow cells were examined by Southern blot analysis using standard methodology. Genomic DNA was isolated from cryopreserved or fresh marrow mononuclear cells using 4 m o m guanidine isothiocyanate-5.7 mom CsCl gradients as First, BamHI-and, in some cases, HindIII-digested genomic DNAs were analyzed with the B859 probe, an 859-bp BamHI fragment of ALL-I cDNA that spans exons 5 through 11, the region of the ALL-I genomic breakpoint c1uster.'2. '8,22 To potentially identify 1 lq23 breakpoints not located within the ALL-l genomic breakpint cluster, select cases were assessed for involvement of a more 5' site in ALL-I . The 5' region of ALL-I was studied in HindIII-or Bgl 11-digested Table 1 . Each child had received a DNA topoisomerase I1 inhibitor or developed secondary leukemia typical of that associated with this therapy. Patients represented a diverse population of children and both sexes. Overrepresentation of any one ethnic background was not apparent. There were nine males and eight females aged from 5 to 14.7 years at onset of the secondary leukemia. Intervals between diagnoses of primary cancer and secondary leukemia ranged from 1 I months to 9 years. Primary
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From Abbreviations: Pt, patient; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MLL, mixed lineage leukemia; MDS, myelodysplastic syndrome; DX, diagnosis; OS, osteosarcoma; HD. Hodgkin's disease; NBL, neuroblastoma; PNET, peripheral neuroectodermal tumor; NHL, non-Hodgkin's lymphoma; RMS, rhabdomyosarcoma; W, white; B, black; H, Hispanic; A-ase, L-asparaginase; ADR, Adriamycin (doxorubicin); AMD, dactinomycin; Ara-C, cytosine arabinoside; BCNU, carmustine; BMT*, bone marrow transplant; CBDCA, carboplatin; Cort**, corticosteroids {dexamethasone, prednisone, methylprednisolone, or intrathecal hydrocortisone); CPPD, cisplatin; CPM, cyclophosphamide: DNM, daunorubicin; EPO, erythropoietin; 5-AZA, 5-azacytidine; HU, hydroxyurea; IFOS, ifosfamide; MIT, mitoxantrone; MTX, methotrexate; PCZ, procarbazine; 6MP, 6-mercaptopurine; 6TG, 6-thioguanine; VCR, vincristine; VLB, vinblastine; VM26, teniposide; VP16, etoposide; XRT, radiation therapy; FAB, French-American-British; DOD, dead of disease; DOC, dead of complications; NED, no evidence of disease.
Cytoreduction regimen not listed.
diagnoses included nine solid tumors and eight leukemias. Nine secondary leukemias were monoblastic variants of AML or mixed lineage leukemia (MLL), one was FAB M1 AML, one was FAB M2, four presented as myelodysplasia (MDS), and two were ALL. In 13 cases, there was previous DNA topoisomerase I1 inhibitor exposure to epipodophyllotoxin in combination with an anthracycline. In two cases, prior treatment was with an anthracycline without epipodophyllotoxin. The only previous DNA topoisomerase I1 inhibitor in one case was dactinomycin and, in another case, no DNA topoisomerase I1 inhibitor was administered.
Karyotypic abnormalities in secondary leukemias. Complete karyotypes of the 17 secondary leukemias are listed in Table 2 . Eleven cases had translocation of chromosome band 1 lq23 with bands lp32,3q25,4~21,9~21-22, or 19p13. One case showed del(1 l)(q23). In five other cases, the karyotypes were normal or suggested unrelated structural abnormalities or only a numerical abnormality. In one case with multiple cytogenetic abnormalities not involving chromosome band l lq23, there were monosomies of chromosomes 5 and 7, more typical of the alkylator-induced myelodysplasias and leukemias (Table 2) .3'.32
Localization of genomic breakpoints in secondary I Iq23 leukemia by Southern blot analysis. Results of Southern blot analysis of 17 cases of pediatric secondary leukemias are shown in Table 2 . Grouped according to whether cytogenetics showed an 1 lq23 translocation and whether there was ALL-I gene rearrangement on Southern blot analysis, cases 1 through 10 were karyotype +/molecular +; cases 1 l through 14, karyotype -/molecular + ; case 15, karyotype +/molecular -; and cases 16 and 17, karyotype -/molecular -.
In 8 of 15 cases with cytogenetic and/or molecular rearrangement of chromosome band llq23, Southem blot analysis of BamHI-digested genomic DNA with the B859 probe showed the normal allele and two additional bands consistent with both derivative chromosomes that resulted from the translocation (Fig l) . In six cases, only one derivative chromosome was detected by the probe. In a previously reported case of etoposide-related AML with a t(l1; 19)(q23;p13), the llq23 translocation breakpoint was The status of the All-7 gene in the breakpoint cluster region and partial karyotypes in cases 1 and 15 were reported previously;" additional molecular analyses of the ALL-7 genomic breakpoint cluster region and the 5' region of ALL-7 in case 15 were performed herein. Case 1 in the present study was case 8 in Winick et al." Cases 1 and 15 were cases 1 and 2, respectively, in Felix et aL1* Cases 3 and 6 were cases 13 and 16, respectively, in Rubin et al.'" Cases 13 and 17 were cases 4 and 6, respectively, in Heyn et al.31 Molecular analyses on case 10 were performed on the cell line B1 derived from the secondary leukemia in a previous case report? ' Abbreviations: R I , one rearrangement; R2, two rearrangements; G, germline.
not located within the ALL-l genomic breakpoint cluster (case 15)." In the present study, this leukemia was further analyzed by hybridization of HindIII-digested DNA with the B859 fragment of ALL-l cDNA, confirming that the translocation breakpoint was not within the region of the breakpoint cluster. Involvement of the 5' region of ALL-l also was excluded. Of l1 cases with cytogenetically detectable abnormalities of chromosome band 1 lq23, 10 had rearrangements within the ALL-l genomic breakpoint cluster. Included was a case of secondary t( 1 1 ; 19) MLL, where the previous Hodgkin's disease therapy included alkylating agents and irradiation, but not a DNA topoisomerase I1 inhibitor (case 5, Tables l   and 2 ).
Four cases of secondary 1 lq23 leukemia with molecular ALL-l gene rearrangements within the breakpoint cluster did not show llq23 abnormalities by karyotype (Table 2) . Included was a case of secondary MDS examined after evolution to secondary AML (case 14). This leukemia showed ALL-l gene rearrangement and a clonal t(11;20)(p15;qll) without cytogenetic evidence of involvement of band 1 lq23 (Table 2) . Similarly, another secondary AML with molecular ALL-l gene rearrangement showed del( 1 l)(q14) by karyotype (case 12). In the child previously treated for embryonal rhabdomyosarcoma with cyclophosphamide, ionozing radiation, and dactinomycin as the only DNA topoisomerase I1 inhibitor, whose clinical course was recently rep~rted,~' there was molecular but not cytogenetic evidence of involvement of the ALL-l gene at band 1 lq23 (case 13, Tables l and 2 ).
DISCUSSION
Secondary leukemia is a complication of effective cancer chemotherapy with epipodophyllotoxins and other DNA topoisomerase I1 inhibitor^.^,^"^^ ALL and non-Hodgkin's lymphoma are the most common primary cancers among affected pediatric patients.".32,34,'7,38 Epipodophyllotoxin-related leukemia also occurs in children after treatment of germ cell tumors, sarcomas, neuroblastoma, and histiocytosis leukemia appears to be i n~r e a s i n g .~. ~~ We examined the clinical, cytogenetic, and molecular diversity in 17 cases of secondary leukemia in children who received topoisomerase I1 inhibitors or developed secondary leukemias typical of those associated with this therapy. Although a period of myelodysplasia often precedes the form of secondary AML associated with alkylating agents and irradiation, leukemias associated with epipodophyllotoxins more commonly present as overt AML.9,32 However, four patients in this series presented with myelodysplasia rather than overt leukemia.
Of 17 cases, 15 had cytogenetic and/or molecular involvement of chromosome band 1 lq23. Molecular rearrangement of the AML-I oncogene at chromosome band 21q22 was not excluded in case 16, which was of FAB M2 morphology and negative for involvement of chromosome band llq23 by both karyotype and Southern blot Cases with the t(15; 17) or inv(l6) were not observed.15"'
The Southern blot results suggest that the clustering of 1 lq23 breakpoints within the ALL-l gene in pediatric secondary leukemias is similar to sporadic c a~e s .~~-*~
The detection of only one derivative chromosome in 6 of 14 cases with molecular rearrangement may be consistent with interstitial deletion of the telomeric region of ALL-l during translocation." Four of 14 cases showed occult molecular rearrangement, a somewhat higher incidence than in karyotype negative sporadic AML.43
x.31.36. 39 The frequency of topoisomerase I1 inhibitor-related
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Most but not all t( 11 ; 19)(q23;p13) molecular breakpoints in sporadic infant leukemia are within the ALL-l genomic breakpoint cluster. 44 In this series, three of four t(l1; 19) secondary leukemia breakpoints localized to the ALL-1 genomic breakpoint cluster. In case 15, the breakpoint was not identified within the ALL-I genomic breakpoint cluster or 5' of this region.'' In four cases of sporadic t( 11; 19)(q23;p13) leukemia, fluorescence in situ hybridization showed I lq23 breakpoints distal to t(4; 1 l), t(9; 1 l), and t(6; 11) cases, but involvement of the more telomeric locus, rck, has been exc l~d e d . ' "~~~ These observations suggest an additional leukemia-associated gene at chromosome band 1 Iq23. PLZF, which also maps to band llq23, is involved in a variant translocation with the retinoic acid receptor-a locus in APL4X but case 15 did not have features of APL.
Novel cytogenetic features also suggest diversity in the pediatric DNA topoisomerase I1 inhibitor-related leukemias. The t(9; 1 l)(p21;q23) commonly identified in cases of epipodophyllotoxin-related AML occurred in only three cases in this series. The t(3; 1 l)(q25;q23) is a variant translocation previously described in case 6."' We determined that the 1 lq23 chromosomal breakage in this case was within the ALL-l genomic breakpoint cluster. The EVII and EAP genes are fused with AML-I at chromosome band 21q22 in variant t(3; 21)(q26;q23) translocations in therapy-related AML and chronic myelogenous l e~k e m i a .~~.~' Whether a common region on chromosome 3q is involved in translocations with both the ALL-l and AML-I genes remains to be explored. Another variant translocation was the t(1; ll)(p32;q23) in therapy-related MDS (case 7).
Epipodophyllotoxin-induced secondary ALL is uncommon in both children and
The secondary ALLs are of B-or T-cell lineage and demonstrate t(4; 11) or t( 11; 16) chromosomal translocations.'2.28,52.53 The del( 1 l)(q23) that we identified in case 8 and mapped molecularly has not been reported in secondary ALL.
Cases 12 and 14 showing the del(ll)(ql4) or t(11;20) (p15;qll) by karyotype had molecular rearrangements of the ALL-l gene at band 1 lq23. There may have been complex translocations or inversions involving chromosome 1 1, or molecular rearrangement of ALL-l independent of the cytogenetically detectable abnormalities. Alternatively, the l lq23 translocations may have appeared falsely in the karyotype as more proximal abnormalities of 1 Iq or of 1 lp. In sporadic leukemias with the t(9; 1 l) involving bands 1 lp13 or llq13, and in leukemias with the t(11;20)(p15;qll), the breakpoints were not explored r n~l e c u l a r l y .~~~~~
The association of epipodophyllotoxins and anthracyclines with secondary leukemia is well-established.9~"~3'"9~'x Dactinomycin without other DNA topoisomerase I1 inhibitors has not previously been associated with secondary 1 lq23
In this study, a case of secondary AML, where the only prior DNA topoisomerase I1 inhibitor exposure was dactinomycin, was shown to have ALL-I gene rearrangement (case 13). Also included in the sarcoma treatment were local irradiation, vincristine, and cyclophosphamide.-" This case suggests that some risk of 1 lq23 leukemia may be associated with dactinomycin. The agent is probably less leukemogenic than the other DNA topoisomerase I1 inhibitors, as this complication has not occurred in survivors of Wilms' tumor. It has also been proposed that the development of llq23 leukemia may be potentiated by alkylating agents in conjunction with DNA topoisomerase I1 inhibitors.31,5R
Case 5 of t( 1 1; 19) secondary AML occurred 15 months after the diagnosis of Hodgkin's disease that was treated with carmustine, cyclophosphamide, vinblastine, procarbazine, and irradiation, a regimen that did not include a DNA topoisomerase I1 inhibitor. Cases 5 and 13 suggest heterogeneity in the agents associated with secondary 1 lq23 leukemia and the mechanism of leukemogenesis.
When used in conjunction with alkylating agents, epipodophyllotoxins may result in secondary AML with characteristic monosomies of chromosomes 5 or 7 as well as 1 lq23 chromosomal trans location^.^ Case 17 of secondary AML after embryonal rhabdomyosarcoma treated with vincristine, doxorubicin, cyclophosphamide, cis-platinum, etoposide, dactinomycin, and irradiation, showed monosomies of chromosomes 5 and 7. There were two translocations, but chromosomal band llq23 was ~ninvolved.~' Molecular ALL-1 gene rearrangement was not present.
Among 15 patients in this series with karyotypic and/ or molecular secondary 1 lq23 leukemia, there was clinical, phenotypic, morphologic, molecular, and cytogenetic heterogeneity. There are some survivors, but the outcome was most often fatal. The clinical efficacy of DNA topoisomerase I1 interactive agents mandates a better understanding of why these drugs are associated with leukemogenic translocations. By genomic cloning and sequencing, potential DNA topoisomerase I1 sites were identified in the ALL-I and AF-9 genes at a t(9; 1 1) breakpoint in sporadic AML.'" This Southern blot analysis provides the framework for further study of the mechanism whereby drug-topoisomerase 11-DNA interactions result in translocations. 
